Sun Yat-Sen University RANID Cohort Initiates Tracking of Satralizumab Pharmacokinetics and Neonatal Safety During Pregnancy
Overview of the RANID Cohort Study
The RANID (Reproductive Age Neuroimmune Diseases) cohort study (NCT07653984), led by the Third Affiliated Hospital of Sun Yat-Sen University in Guangzhou, China, began recruiting patients on April 21, 2024. This prospective observational study enrolls a total of 100 participants, including 50 female patients of reproductive age (20-55 years) with neuroimmune diseases and 50 healthy controls, to track the disease course before, during, and after pregnancy for up to 25 months. Wei Qiu, the principal investigator, is an experienced clinician who has managed a cohort of 461 NMOSD patients and conducted research on immunoadsorption therapy, making him a leading figure in the neuroimmune field in China, which supports the reliability of the study design.
Target Diseases and Study Design
This study is noteworthy because it simultaneously tracks six neuroimmune diseases within a single cohort. It comparatively observes NMOSD (Neuromyelitis Optica Spectrum Disorder), MS (Multiple Sclerosis), Autoimmune Encephalitis, Myasthenia Gravis, GBS (Guillain-Barré Syndrome), and MOGAD within a unified framework. The primary outcome measures include the annualized relapse rate (ARR) before, during, and after pregnancy, maternal complications (including miscarriage, gestational diabetes, and preeclampsia), and neonatal growth indicators. Extensive biomarkers, such as cytokines, antibodies, and neurofilament light chain (NfL), are also measured in blood, cerebrospinal fluid, and placental tissue. Unlike existing single-disease observational studies, this design allows for a direct comparison of pregnancy outcomes across multiple neuroimmune diseases.
Collection of Satralizumab Pharmacokinetic Data
A key differentiating factor of the study is the simultaneous measurement of maternal serum concentrations and neonatal levels of satralizumab (Enspryng), an IL-6 receptor antagonist developed by Roche/Chugai Pharmaceutical. Satralizumab is an AQP4-IgG-positive NMOSD treatment that received FDA approval in 2020, and in 2025, data on relapse rate reduction for MOGAD indication will be presented at AAN. Although animal studies have confirmed its presence in breast milk, human data on breastfeeding safety are lacking. Therefore, the maternal-neonatal pharmacokinetic (PK) data generated by RANID can serve as the first systematic evidence for the use of satralizumab during pregnancy and breastfeeding.
Market Context and Competitive Landscape
The global neuroimmune disease therapeutics market is expected to reach approximately USD 41.15 billion in 2026 and grow to USD 91.88 billion by 2035 (CAGR of 8.9%). The NMOSD market alone is projected to expand from USD 528.35 million in 2024 to USD 836.28 million in 2033. Currently, the FDA-approved NMOSD treatments include eculizumab (Soliris, Alexion/AstraZeneca, 2019), inebilizumab (Uplizna, Horizon/Amgen, 2020), satralizumab (Enspryng, Roche/Chugai, 2020), and ravulizumab (Ultomiris, Alexion/AstraZeneca, 2024). As the differences in relapse inhibition efficacy among these four drugs narrow, the availability of safety data in special patient populations, such as pregnant women and children, is becoming a key differentiating factor in prescribing decisions.
NMOSD and MS, among other neuroimmune diseases, have a female incidence rate 3 to 9 times higher than that of males. Whether women of childbearing age can continue treatment without interruption and plan for pregnancy is a critical factor that simultaneously affects patient quality of life and market share of therapeutics. The maternal-neonatal pharmacokinetic data on satralizumab generated by the RANID cohort can be used by Roche/Chugai to establish a leading position in providing safety labeling for pregnant women, competing against eculizumab and ravulizumab (Alexion/AstraZeneca) and inebilizumab (Horizon/Amgen). In a market where the efficacy differences among the four approved drugs for NMOSD (USD 5.28 billion in 2024) are diminishing, the availability of real-world evidence (RWE) in special patient populations is becoming a key factor in determining prescribing patterns. The expected release of primary results in 2030 will coincide with the BEST-NMOSD comparative efficacy clinical trial (NCT07010302), and the data will serve as a foundation for reshaping the NMOSD treatment paradigm.
Source: ClinicalTrials.gov (api_ct)